Clinical Trial Update: Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant [Phase 2]

View source ↗

Summary

A Phase 2 study assessing the combination of bortezomib and vorinostat in multiple myeloma patients after autologous stem cell transplantation, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)
• Zolinza (vorinostat)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-29